Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R)

Cell Biochemistry and Function

Volumn 26, Issue 4, 2008, Pages 467-477

  Wu, Yong Yang ^a   Li, Hong ^a   Lv, Xiao Yan ^a   Wei, Qiang ^a   Li, Xiang ^a   Liu, Xin Yu ^a   Zhou, Qin ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Androgen independent; EGF R; JKTBP; Prostate cancer

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR RECEPTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D LIKE PROTEIN; NUCLEAR PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN LNCAP; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; UPREGULATION;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; ENZYME ACTIVATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBONUCLEOPROTEINS;

EID: 46749098329     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1468     Document Type: Article

References (43)

1. Kamei D, Tsuchiya N, Yamazaki M, Meguro H, Yamada M. Two forms of expression and genomic structure of the human heterogeneous nuclear ribonucleoprotein D-like JKTBP gene (HNRPDL). Gene 1999; 228: 3-22.
2. Tsuchiya N, Kamei D, Takano A, Matsui T, Yamada M. Cloning and characterization of a cDNA encoding a novel heterogeneous nuclear ribonucleoprotein-like protein and its expression in myeloid leukemia cells. J Biochem 1998; 123: 499-507.
3. Carpenter B, Mackay C, Alnabulsi A, et al. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 2006; 1765: 85-100.
4. Yeap BB, Voon DC, Vivian JP, et al. Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3′-untranslated region of the androgen receptor messenger RNA. J Biol Chem 2002; 277: 27183-27192.
5. Wilce JA, Leedman PJ, Wilce MCJ. RNA-binding proteins that target the androgen receptor mRNA. IUBMB Life 2002; 54: 345-349.
6. Balmer LA, Beveridge DJ, Jazayeri JA, Thomson AM, Walker CE. Identification of a novel AU-rich element in the 3′-untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding protein. Mol Cell Biol 2001; 21: 2070-2084.
7. Kuruma H, Egawa S, Oh-Ishi M, et al. High molecular mass proteome of androgen-independent prostate cancer. Proteomics 2005; 5: 1097-1112.
8. Suzuki T, Shimizu T, Satoh K, Sugibayashi R, Takeda K. Differential expression of genes during TPA-induced differentiation of human prostatic cancer TSU-Pr1 cells. Int J Mol Med 2002; 10: 735-739.
9. Nakamoto T, Okada H, Nakajima T, Ikuta A, Yasuda K, Kanzaki H. Progesterone induces the fibulin-1 expression in human endometrial stromal cells. Hum Reprod 2005; 20: 1447-1455.
10. Kwabi-Addo B, Wang JH, Erdem H, et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004; 64: 4728-4735.
11. Dahiya R, Lee C, Haughney PC, Chui R, Ho R, Deng G. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines. Urology 1996; 48: 963-970.
12. Shi XB, Ma AH, Tepper CG, et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004; 60: 257-271.
13. Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackbun GL. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 2004; 110: 800-806.
14. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992; 147: 956-961.
15. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-556.
16. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001; 61: 1919-1926.
17. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-3555.
18. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nature Med 2004; 10: 33-39.
19. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566-1573.
20. Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis 2004; 25: 517-525.
21. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999; 5: 280-285.
22. Ruiter GA, Verheij M, Zerp SF, Moolenaar WH, Van Blitterswijk WJ. Submicromolar doses of alkyl-lysophospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cells. Int J Cancer 2002; 102: 343-350.
23. Golubovskaya V, Beviglia L, Xu LH, Earp HS, 3rd, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277: 38978-38987.
24. Weighardt F, Biamonti G, Riva S. The roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. Bioessays 1996; 18: 747-756.
25. Krecic AM. Swanson MS. hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 1999; 11: 363-371.
26. Carpenter B, MacKay C, Alnabulsi A, et al. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 2005: 1765: 85-100.
27. Gouble A, Grazide S, Meggetto F, Mercier P, Deslsol G, Morello D. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice. Cancer Res 2002; 62: 1489-1495.
28. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C. Murray GI. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006: September 5 [Epub ahead of print].
29. Lee EJ, Kim SH, Kwark YE, Kim J. Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma. Exp Mol Med 2006; 38: 203-209.
30. Sommer S, Cui Y, Brewer G, Fuqua SA. The c-Yes 3′-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J. Steroid Biochem Mol Biol 2005; 97: 219-229.
31. Boopathi E, Lenka N, Prabu SK, et al. Regulation of murine cytochrome c oxidase Vb gene expression during myogenesis: YY-1 and hnRNPD (JKTBP-1) proteins reciprocally regulate the transcription. J Biol Chem 2004: 279: 35242-35254.
32. Visakorpi T, Kallioniemi OP, Koivula T, Harvey J, Isola J. Expression of epidermal growth factor receptor and erbB-2 (HER-2/neu) oncoprotein in prostatic carcinoma. Mol Pathol 1992; 5: 643-648.
33. Hakariya T, Shida Y, Sakai H, Kanetake H, Igawa T. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells. Biochem Biophys Res Commun 2006; 342: 92-100.
34. Gil-Diez DM, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005-1012.
35. Kumar VL, Majumder PK, Gujral S, Kumar V. Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. Cancer Lett 1998; 134: 177-180.
36. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3444.
37. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-5478.
38. Nazareth LV, Wigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996; 271: 19900-19907.
39. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand independent activation of the androgen receptor by IL-6 and the role of the coactivator SRC-1 in prostate cancer cells. J Biol Chem 2002; 277: 38087-38094.
40. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999; 6: 487-502.
41. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.
42. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. ErbB-2 signaling is involved in regulating PSA secretion in androgen independent human prostate cancer LNCaP C-81 cells. Oncogene 2003; 22: 781-796.
43. Jimeno A, Rubio-Viqueira B, Amador ML, et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005; 65: 3003-3010.